Chimerix Announces Upcoming Presentations at the Society for Neuro-Oncology Annual Meeting 2021

Rhea-AI Summary

Chimerix (NASDAQ:CMRX), a biopharmaceutical company, announced its data presentations at the Society for Neuro-Oncology Annual Meeting 2021 in Boston from November 19-21, 2021. The late-breaking plenary oral presentation titled "Clinical efficacy of ONC201 in recurrent H3 K27M-mutant diffuse midline glioma patients" will occur on November 20, 2021. Additional presentations will cover ONC201's activity and safety in various glioma cases. Chimerix is committed to developing treatments for deadly diseases and recently received FDA approval for TEMBEXA to treat smallpox.

DURHAM, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced upcoming data presentations at the Society for Neuro-Oncology (SNO) Annual Meeting 2021, which will be held in Boston, MA from November 19-21, 2021.

Details for the late-breaking plenary oral presentation are as follows:

Title: Clinical efficacy of ONC201 in recurrent H3 K27M-mutant diffuse midline glioma patients
Abstract Number: LTBK-05
Date and Time: November 20, 2021 from 9:37 a.m. – 9:50 a.m. ET
Presenter: Isabel Arrillaga-Romany, M.D., Ph. D., Massachusetts General Hospital

Details for additional oral and poster presentations are as follows:

Title: Single agent activity of ONC201 in non-midline H3 K27M-mutant diffuse gliomas
Abstract Number: CTNI-27
Date and Time: November 19, 2021 from 7:30 p.m. - 9:30 p.m. ET
Presenter: Yazmin Odia, M.D., M.S., FAAN, Miami Cancer Institute

Title: Safety of ONC201 administered two consecutive days per week in pediatric H3 K27M-mutant glioma patients
Abstract Number: CTNI-36
Date and Time: November 19, 2021 from 7:30 p.m. - 9:30 p.m. ET
Presenter: Sharon L. Gardner, M.D., New York University School of Medicine

Title: Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose has a strong antiproliferative effect on medulloblastoma cells
Abstract Number: EXTH-68
Date and Time: November 19, 2021 from 7:30 p.m. - 9:30 p.m. ET
Presenter: Georg Karpel-Massler, M.D., Ph.D., Ulm University

Title: Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma
Abstract Number: TAMI-17
Date and Time: November 19, 2021 from 7:30 p.m. - 9:30 p.m. ET
Presenter: Trang T. Nguyen, Ph.D., Columbia University

Title: Harnessing Cellular Stress for Immune Targeting of DIPGs
Abstract Number: EXTH-30
Date and Time: November 19, 2021 from 7:30 p.m. - 9:30 p.m. ET
Presenter: Donghang Cheng, Ph.D., University of Texas MD Anderson Cancer Center

Title: Serial plasma and CSF cell-free tumor DNA (cf-tDNA) tracking in diffuse midline glioma patients undergoing treatment with ONC201
Abstract Number: BIOM-28
Date and Time: November 21, 2021 from 11:35 a.m. – 11:45 a.m. ET
Presenter: Evan Cantor, M.D., J.D., Washington University at St. Louis

About Chimerix

Chimerix is a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure. The Company has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT). ONC201 is in development for recurrent H3 K27M mutant glioma. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia.

CONTACT:

Investor Relations:        
Michelle LaSpaluto
919-972-7115
ir@chimerix.com 

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com 

FAQ

What are the upcoming presentations for CMRX at the SNO Annual Meeting 2021?

Chimerix will present data on ONC201 at the SNO Annual Meeting 2021 in Boston from November 19-21, 2021, including a late-breaking presentation on November 20.

When is the oral presentation on ONC201's clinical efficacy by Chimerix?

The oral presentation on ONC201's clinical efficacy will take place on November 20, 2021, from 9:37 a.m. to 9:50 a.m. ET.

What is the focus of Chimerix's research on ONC201?

Chimerix's research on ONC201 focuses on its efficacy in treating recurrent H3 K27M-mutant diffuse midline gliomas.

What other presentations will Chimerix deliver at the SNO Annual Meeting 2021?

Chimerix will present on ONC201's single-agent activity, safety in pediatric patients, metabolic reprogramming effects, and more at the SNO Annual Meeting.

What recent FDA approval did Chimerix receive?

Chimerix received FDA approval in June 2021 for TEMBEXA as a treatment for smallpox.